 Exclusion Criteria: - Prior phototherapy - Current or prior treatment with any tumor necrosis factor TNF antagonist, including etanercept, infliximab and adalimumab - Erythrodermic, pustular or guttate psoriasis - Evidence of skin conditions e.g., eczema other than psoriasis that would interfere with study-related evaluations of psoriasis - Evidence of active infections such as fevers, chills, sweats, or history of untreated Lyme disease and active severe infections within 4 weeks before screening visit or between the screening and baseline visits - History of immune compromised health e.g., human immunodeficiency virus HIV positive status - History of any cutaneous malignancy at any time, including squamous or basal cell carcinomas or melanoma - History of non-cutaneous cancer within 5 years - Actinic keratosis or atypical moles - History of alcohol or drug abuse within 12 months of screening visit - Current enrollment in another clinical study and treatment with another experimental drug or approved therapy for experimental use within 30 days prior to etanercept administration - Severe comorbidities as outlined in ENBRELr Package Insert: diabetes mellitus requiring insulin, congestive heart failure of any severity, myocardial infarction within less than or equal to 52 weeks before screening, unstable angina pectoris, oxygen-dependent severe pulmonary disease, tuberculosis or tuberculosis exposure, chronic hepatitis B or hepatitis C, systemic lupus erythematosus, history of multiple sclerosis or other demyelinating disease, transverse myelitis, optic neuritis or epilepsy, uncontrolled hypertension defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg - Contraindications according to the ENBRELr Package Insert - Evidence of open cutaneous ulcers - Evidence of photosensitivity disorder e.g., polymorphous light eruption - Nursing mothers, female subjects planning on becoming pregnant or male subjects planning a pregnancy with their spousepartner while in the study - Subjects that cannot commit to all the assessments required by the protocol - Known photosensitivity or known sensitivity to any of the excipients or products to be administered during dosing - Any disorder that compromises the ability of the subject to give written informed consent andor to comply with study procedures 